To determine if the use of nimodipine reduces the severity of ischemic deficits secondary to vasospasm.
- Nimodipine (Nimotop®)Drug
Intervention Desc: Calcium channel blocker (L-type calcium channels)
Prospective, randomized, double blind, placebo-controlled trial of 70 patients.
Patients were randomized to receive nimodipine orally (60 mg every four hours) or placebo for 21 days. Tranexamic acid (6 g/day) was also administered to most patients.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Glasgow Outcome Scale score at the end of treatment.|